

PRESS RELEASE
31 January 2022 14:00:00 CET



Regional politician wants TUMT to be used in all hospital groups in Västra Götaland

Heikki Klaavuniemi, Regional Council SD, questions in a letter to Skövde Nyheter today why the treatment of benign prostate enlargement is not equal in Västra Götaland.

TUMT, transurethral microwave therapy, is the medical term for ProstaLund's treatment of benign prostate enlargement, CoreTherm. TUMT is currently performed only at three of Västra Götaland's hospitals, which Heikki Klaavuniemi, regional councillor SD, questions in today's letter in Skövde Nyheter. He points out, among other things, that "it poses difficulties in the person-centered care where patients can be offered different existing treatment methods and be involved in the choice of treatment method."

According to Klaavuniemi, SD has been in contact with the chairman in the urology coordination council who reportedly stated that the TUMT method is significantly cheaper than a TURP operation and that the duration of the treatment is good and that the method has a good evidence position.

According to the sender, the Sweden Democrats have now brought a so-called initiative case in the Health Care Board where they want to investigate, among other things, the possibility of spreading the TUMT method to the remaining hospital groups in the Västra Götaland region.

CEO Johan Wennerholm comments: "It is very gratifying that more and more politicians from left to right are engaging with the gentlemen with prostate enlargement and that they at the same time see what profits CoreTherm can generate. It will be exciting to follow the Sweden Democrats' initiative case in Västra Götaland."

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
31 January 2022 14:00:00 CET

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Regional politician wants TUMT to be used in all hospital groups in Västra Götaland